Mike Trower

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial”.

Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial

Menopause The Journal of The North American Menopause Society(2020)10.1097/gme.0000000000001500

N/A

3.1DataRank · unranked

77 citations

Richard A. Anderson, Elizabeth Ballantyne, Hadine Joffe, Mary Kerr, Steve Pawsey +1 more

Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial

BMJ Open(2020)10.1136/bmjopen-2019-030114

N/A

0.863DataRank · unranked

14 citations

Mike Trower, Ajay Duggal, Pamela Guglielmini, Peter Q. Harris, David M. Jackson +6 more

Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1)

Menopause The Journal of The North American Menopause Society(2023)10.1097/gme.0000000000002138

N/A

0DataRank · unranked

84 citations

Richard A. Anderson, Elizabeth Ballantyne, James A. Bolognese, Cecilia Caetano, Hadine Joffe +8 more